

2024 World Conference on Lung Cancer

SEPTEMBER 7-10, 2024 | SAN DIEGO, CA USA



Mesothelioma and Thymoma – Limited and Advanced Stage

Shiruyeh Schokrpur, MD, PhD Assistant Professor UC Davis Health

10/5/2024




2024 World Conference on Lung Cancer

SEPTEMBER 7-10, 2024 | SAN DIEGO, CA USA

Mesothelioma

- Rare cancer affecting approximately 40,000 people worldwide
- Most commonly linked to asbestos exposure, but over 10% have an inherited predisposition, including *BAP1* loss
- Role of surgery is controversial and immunotherapy has revolutionized management based on CheckMate 743



Nowak et al. JCO Onc. Prac. 2021

BEST OF




Perioperative Chemoimmunotherapy for Mesothelioma

Michael Offin, MD Memorial Sloan Kettering Cancer Center USA






MARS2 randomized patients to pleurectomy decortication and noted inferior OS with surgery




Lim E, et al, Lancet Resp 2024.

BEST OF


2024







Epithelioid




Content on this presentation is property of the author and licensed by the IASLC. Copyright permission from the IASLC is required for reuse.

С



Prospective trial of neoadjuvant platinum/pemetrexed + nivolumab (NCT04162015)



Key Inclusion Criteria:

- Operable/Resectable
- KPS ≥ 70%
- Platinum/pemetrexed/ ICI naïve

Primary Objective:

 Attempted P/D within 30 days of the planned surgery date

Secondary Objective:


- Safety
- Overall survival (OS) from treatment start
- Progression free survival (PFS)

Offin M., et al, ASCO, 2024






Best overall response to neoadjuvant chemo/nivolumab by modified (m)RECIST (NCT04162015)





Offin M., *et* al, ASCO, 2024




Tertiary Lymphoid Structures (TLS) potentially correlate with clinical outcomes








NCT04162015









Mesothelioma: Molecular Landscape and Histological Terrain

Ibiayi Dagogo-Jack, MD


Massachusetts General Hospital

USA





Alterations in Epithelioid vs Non-Epithelioid




2024



Impact of Molecular Alterations on Prognosis


	Total (n=194)	Low risk (n=142)	High risk (n=52)		OR (95% CI)	p value	MTAP Status (TCGA + N
CDKN2B deletion	54 (28%)	14	40		29.54 (12.12-78.20)	3·99×10 ⁻¹⁹	N=139
CDKN2A deletion	57 (29%)	17	40	=>	23.87 (10.08-60.81)	1·32×10 ⁻¹⁷	p-value = 5e-05
TERT	12 (6%)	1	11		37.05 (5.12-1624.76)	2.09×10 ⁻⁶	L00% +
NF2	46 (24%)	22	24		4.63 (2.16-10.08)	3.66×10⁻⁵	T
TP53	23 (12%)	8	15		6.70 (2.45–19.77)	4·18×10 ⁻⁵	
LATS2	12 (6%)	4	8	_	6.20 (1.57–29.52)	0.0034	% 80%
SETD2	22 (11%)	21	1	<	0.11 (0.00-0.75)	0.0099	
BAP1	70 (36%)	59	11		0.38 (0.16-0.83)	0.011	Survival 8
BAP1 deletion	23 (12%)	13	10		2.35 (0.86–6.30)	0.077	·\$ 60% \]
PBRM1	8 (4%)	8	0	B	0.00 (0.00-1.57)	0.11	
FBXW7	6 (3%)	6	0	B	0.00 (0.00-2.31)	0.20	
PTEN	4 (2%)	2	2		2.78 (0.20-39.35)	0.29	
LATS1	7 (4%)	4	3		2.10 (0.30–12.91)	0.39	
CDKN2A	4 (2%)	4	0	B	0.00 (0.00-4.15)	0.58	❷ \ \ " [™] "h
ABL1	4 (2%)	4	0	8	0.00 (0.00-4.15)	0.58	$\delta^{20\%}$
CREBBP	7 (4%)	6	1		0.45 (0.01–3.82)	0.68	
PIK3CA	4 (2%)	3	1		0.91 (0.02–11.62)	1	
BAP1 fusion	8 (4%)	6	2		0.91 (0.09–5.29)	1	0% 0 50 100 150
WT1 amplification	5 (3%)	4	1		0.68 (0.01–7.06)	1	0 50 100 150 Months
				0.01 10 30			монсиз



BEST OF 2024



Exploiting Meso Therapeutic Vulnerabilities



Engstrom Cancer Discovery 2023

2024



Advances in Mesothelioma Immunology


Hyun-Sung Lee, M.D., Ph.D.

Systems Onco-Immunology Laboratory David J. Sugarbaker Division of Thoracic Surgery Michael E. DeBakey Department of Surgery Baylor College of Medicine, Houston TX, USA





Triad (CD4+CD8+DC): Co-localization of immune cells




Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumors: Espinosa-Carrasco,..., Burt, Lee, Schietinger. Cancer Cell 2024





MPM Immunoproteogenomics







Determinants of response/resistance to ICB for MPM

Immune Checkpoint Treatment	Favorable	Unfavorable	
Intrinsic	BAP1 mutation Tumor PD-L1 (+) Non-epithelioid	9p21.3 loss Tumor PD-L1(-) Epithelioid	
Extrinsic	TLS, Triads, NK-like T	CAF, TAMs	
Immunogenetics	HLA-A*02:01	HLA-A*03:01/24:02	
pMHC-I Cluster	1	2 or 3	
Liquid biomarker	Low SMRP	High SMRP	





Targeting TROP-2 in Diffuse Pleural Mesotheliomas

Michael Offin, MD

Memorial Sloan Kettering Cancer Center

United States






TROP-2 expressing cell lines lead to increased in vivo metastatic potential


Intracardiac injection:

 TROP-2 expressing and induced cell lines lead to increased metastasis


 TROP-2 low and knockout cell lines lead to decreased metastatic potential
 H28 H2452 MSTO-211H (Epithelioid) (Epithelioid) (Biphasic)
 Improve description of the second Day 15




Trop-2 OE



Trop-2 KO



Control




Offin et al., under review






We demonstrated *in vivo* activity and a potential pathway of resistance with Sacituzumab govitecan in our PDX models







- A. Determine TROP-2 expression in biopsy samples
 identify a critical minimum threshold (if any) of expression
 - identify a critical minimum threshold (if any) of expression for SG activity
 - correlate expression with clinicopathologic features and pathway changes
- B. Define the role of PI3K-AKT activation and mechanistic changes in DPM tumor samples treated with SG



response to SG in paired tumor samples



PEMbrolizumab Plus Lenvatinib In Second-Line Pleural MEsotheLiomA Patients: A Single Arm Phase II Study - PEMMELA (second cohort)

L.H. Douma, V. van der Noort, F. Lalezari, J. de Vries, M. Vermeulen, B. Schilder, I. Smesseim, P. Baas, J.A. Burgers, C.J. de Gooijer


> Netherlands Cancer Institute Department of Thoracic Oncology





Trial Design


Single-arm, single-center, phase II study





Objective Response Rate

	Local investigator	Independent central reviewer (2 nd endpoint)
	PEM+LEN (N=20)	PEM+LEN (N=20)
Objective response (95% CI) -%	60 (39-82)	45 (23-67)
Best overall response – n(%)		
CR	1 (5)	0 (0)
PR	11 (55)	9 (45)
SD	6 (30)	10 (50)
PD	2 (10)	1 (5)






BEST OF

2024

X= PD as best response nivo/ipi







mPFS 7.0 months (95% CI 5.5 – NA)

	Grade 1-2 n,(%)	Grade 3 n,(%)	Grade 4 n,(%)
Fatigue	14 (70)	1 (5)	0
Dysphonia	12 (60)	0	0
Anorexia	7 (35)	1 (5)	0
Diarrhea	9 (45)	0	0
Hypertension	4 (20)	5 (25)	0
Oral pain	7 (35)	0	0
Malaise	3 (15)	3 (15)	0
Proteinuria	4 (20)	0	0
Hyponatremia	0	0	1 (5)
Neutrophil count decreased	0	0	1 (5)
Respiratory failure	0	0	1 (5)





Thymoma



- Originates from epithelial cells of the thymus
- Symptoms such as chest pain, cough, phrenic nerve palsy can arise from mass effect
- Paraneoplastic syndromes including MG, PRCA, hypogammaglobulinemia, pancytopenia, and collagen vascular disease can occur with thymoma
- Treatment can involve surgery, radiation, and chemotherapy



Kumawat et al. APJCC. 2024




Validity of simple thymomectomy for clinical stage I thymoma without myasthenia gravis:a propensity score-matched analysis

Tomoyuki Hishida, Takahiro Suzuki, Seiji Omura, Yu Okubo, Kyohei Masai, Kaoru Kaseda, and Keisuke AsakuraDivision of Thoracic Surgery, Department of Surgery, Keio University School of Medicine, Tokyo, Japan






The modes of resection of thymomas



Has been recommended as a standard mode of resection for all thymomas.¹



Has been widely introduced for early stage thymomas without myasthenia gravis (MG).^{2,3}





Patients and methods


- A total of 119 consecutive patients who underwent surgery for clinical stage I thymoma without MG (cT1N0M0 in the 8th TNM) or a suspected lesion which was diagnosed with thymoma at final pathology between 2003 to 2018 at our institution.
- "Simple" or "Total" was determined by a multidisciplinary treatment board, but recent trend favored "Simple" using minimally invasive approaches if the tumor was <5 cm preoperatively.
- "Total" was performed according to extended thymectomy proposed by Masaoka et al.¹
- We conducted a one-by-one propensity score-matched analysis to reduce potential selection biases between "Simple" and "Total".

¹Masaoka, A, et al. Ann Thorac Surg 1996;62:853-9.



Survival outcomes (after PS matching)

- Matched with 4 preoperative factors (age, gender, preoperative size, anti-AchR antibody)
- Forty patients in each group were compared.





Detailed long-term outcomes

	Simple thymomectomy (N = 50)	Total thymectomy (N = 69)
Thymoma recurrence	3 (6%) (Local: 2, lung: 1)	3 (4%) (Dissemination)
Preoperative size	All were ≥5 cm	All were ≥5 cm
Recurrence in ≥5 cm tumor	38% (3/8)	10% (3/29)
Death	3 (6%) (Thymoma: 2, gastric cancer: 1)	3 (4%) (Pneumonia: 2, unknown: 1)
Postoperative MG	0	<mark>3 (4%)</mark> (<1M, 3M, 1Y9M)
Postoperative autoimmune diseases other than MG	0	3 (4%) (Basedow disease: 2, SLE: 1)

